« Return to News | Awards & Advancement

NIH awards Avaxia Biologics $1.5 million for bowel disease

Monday, March 19, 2012 10:57 AM

Avaxia Biologics, a privately-held biotech company based in Lexington, Mass., has received a second round of funding from the National Institutes of Health (NIH) to develop orally-active antibody therapeutics for the treatment of inflammatory bowel disease (IBD).

The phase II Small Business Innovation Research (SBIR) grant was awarded to Avaxia by a branch of NIH, the National Institute of Diabetes and Digestive and Kidney Diseases. The grant awards $1.5 million in funding over two years and was based on the successful completion of a phase I SBIR award that demonstrated efficacy of AVX-470 in mouse model systems of inflammatory bowel disease.

"Generated under prior funding of the NIH, our orally active anti-TNF antibody significantly reduced inflammatory bowel disease severity in three different animal models and showed superior efficacy to an oral steroid drug in a comparative test of disease remission,” said Barbara S. Fox, founder and CEO, Avaxia. “With these impressive results, and with the support of this phase II SBIR grant, Avaxia plans to enter into clinical trials with AVX-470 in patients with IBD this year. AVX-470 appears to be on track to be the first orally-active anti-TNF antibody for IBD."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.